---
schema_version: "secwatch.filing_event.v1"
accession: "0000012208-22-000065"
form_type: "8-K"
ticker: "BIO"
cik: "0000012208"
company_name: "BIO-RAD LABORATORIES, INC."
filed_at: "2022-10-27T23:59:59+00:00"
generated_at: "2026-06-22T23:40:21.579169+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Bio-Rad Q3 sales $680.8M (-8.9% YoY); non-GAAP EPS $2.60 vs $3.71; FY22 guidance reaffirmed

## Summary
- Q3 net sales $680.8M, down 8.9% YoY; currency-neutral core sales (ex-COVID and legal settlements) grew 6.1%.
- GAAP net loss $164.2M ($5.52 loss per diluted share) vs income $3,928M in Q3 2021, driven by Sartorius fair-value swings.
- Non-GAAP net income $77.9M ($2.60 diluted EPS) vs $112.2M ($3.71) in Q3 2021.
- Life Science segment sales $317.9M (-14.9% YoY); Clinical Diagnostics $361.9M (-2.8% YoY; +3.0% currency-neutral).
- FY22 guidance: non-GAAP currency-neutral revenue growth at high end of prior 1.0-2.0%; COVID revenue now ~$105M; operating margin ~19.0%.

## SEC filing metadata
- accession: 0000012208-22-000065
- form_type: 8-K
- ticker: BIO
- cik: 0000012208
- company_name: BIO-RAD LABORATORIES, INC.
- filed_at: 2022-10-27T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/0000012208-22-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/bio-20221027.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000012208-22-000065
- JSON: https://secwatch.observer/filing/0000012208-22-000065.json
- Plain text: https://secwatch.observer/filing/0000012208-22-000065.txt

## Key facts
- Earnings Releases
  BIO-RAD LABORATORIES, INC. reported the third quarter ended September 30, 2022 results: revenue $680.8 million, net income $164.2 million, or a loss of $5.52 per share, on a diluted basis.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $680.8 million
  - Net income: $164.2 million, or a loss of $5.52 per share, on a diluted basis
  - Result: reported results
  source text: in life science research and clinical diagnostic products, today announced financial results for the third quarter ended September 30, 2022. Third-quarter 2022 net sales were $680.8 million, a decrease of 8.9 percent compared to $747.0 million reported for the third quarter of 2021. COVID-related revenue was approximately $17 million in the third quarter of 2022
  evidence_url: https://www.sec.gov/Archives/edgar/data/12208/000001220822000065/0000012208-22-000065-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.